New oral anticoagulants in atrial fibrillation

European Heart Journal

Volumn 29, Issue 2, 2008, Pages 155-165

  Turpie, Alexander G G ^a  

^a HHS General Hospital   (Canada)

Author keywords

Anticoagulant; Atrial fibrillation; Direct thrombin inhibitor; Factor Xa inhibitor; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DU 176B; ENOXAPARIN; HEPARIN; IDRAPARINUX; MELAGATRAN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; RIVAROXABAN; THROMBIN; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN; YM 150;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; CHRONIC DISEASE; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBIN; THROMBOEMBOLISM;

EID: 38349147756     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm575     Document Type: Review

References (94)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation- executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27:1979-2030.
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-473.
3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
4. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, Stijnen T, Lip GYH, Witteman JCM. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-953.
5. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:429S-456S.
6. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-125.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
8. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003;22:118-123.
9. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-1764.
10. Penado S, Cano M, Acha O, Hernandez JL, Riancho JA. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med 2003;114:206-210.
11. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
12. Glazer NL, Dublin S, Smith NL, French B, Jackson LA, Hrachovec JB, Siscovick DS, Psaty BM, Heckbert SR. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med 2007;167:246-252.
13. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204S-233S.
14. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449- 1457.
15. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, Nalysnyk L. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004;126:1938-1945.
16. Murray M, Wild D, Reaney M. Exploring patient satisfaction with long-term warfarin for the treatment of atrial fibrillation. (Abstract 2245). Blood 2005;106.
17. Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006;134:3-19.
18. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005;3:1843-1853.
19. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006;15:843-855.
20. Dahl OE. Orthopaedic surgery as a model for drug development in thrombosis. Drugs 2004;64(Suppl. 1):17-25.
21. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S-428S.
22. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-1040.
23. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-1698.
24. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-698.
25. Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin 2006;22:471-481.
26. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstrom T, Berkowitz SD, Nystrom P, Thorsen M, Ginsberg JS. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-689.
27. Morishima Y, Fukuda T, Tsuji N, Honda Y, Matsumoto C, Furugohri T, Shibano T. A thrombin inhibitor, but not a Factor Xa inhibitor, DU-176b, aggravates tissue factor-induced hypercoagulation in rats. ASH Annual Meeting Abstracts 2005;106:1878.
28. Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB et al. Evidence for a rebound coagulation phenomenon after cessation of a 4 h infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993;21:1039-1047.
29. Bijsterveld NR, Moons AH, Meijers JC, Tijssen JG, Buller HR, Levi M, Peters RJ. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002;39:811-817.
30. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, v.Dijk N, Frostick SP, Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate is effective and safe for the extended prophylaxis of venous thromboembolism following total hip replacement. (Abstract O-W-049). J Thromb Haemost 2007;5.
31. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-956.
32. Friedman RJ, Caprini JA, Comp PC, Davidson BL, Francis CW, Ginsberg J, Huo M, Lieberman JR, Muntz J, Raskob G, Clements ML, Hantel S, Schnee J. Dabigatran etexilate versus enoxaparin in preventing venous thromboembolism following total knee arthroplasty. (Abstract O-W-051). J Thromb Haemost 2007;5.
33. Ezekowitz MD, Reilly P, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, pedersen KE, Lionetti DA, Stangier J, Wallentin L. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007, in press.
34. Rai R, Sprengeler PA, Elrod KC, Young WB. Perspectives on factor Xa inhibition. Curr Med Chem 2001;8:101-119.
35. Leadley RJ Jr. Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem 2001;1:151-159.
36. Becker RC, Alexander JH, Dyke C, Huang Y, Saint-Jacques H, Hasselblad V, Harrington RA, Bovill EG. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. Thromb Res 2006;117:439- 446.
37. Howard AW, Aaron SD. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials. Thromb Haemost 1998;79:902-906.
38. Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;60:407-410.
39. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-1840.
40. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867-873.
41. Padilla A, Gray E, Pepper DS, Barrowcliffe TW. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Br J Haematol 1992;82:406- 413.
42. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188S-203S.
43. The PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004;2:47-53.
44. Buller HR. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep-vein thrombosis or pulmonary embolism. (Abstract 6). Blood 2006;108.
45. Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007;5:746-753.
46. Iwatsuki Y, Shigenaga T, Moritani Y, Suzuki M, Ishihara T, Hirayama F, Kawasaki T. Biochemical and pharmacological profiles of YM150, an oral direct Factor Xa inhibitor. (Abstract 911). Blood 2006;108.
47. Eriksson BI, Turpie AGG, Lassen MR, Prins MH, Agnelli G, Gaillard ML, Meems B. YM150, an oral direct Factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery. A dose escalation study. (Abstract 1865). Blood 2005;106.
48. Nogimori M. Overview of the Business Results for IH/FY2006. http://www.astellascom/global/ir/library/pdf/h_pre2007_eg.pdf1106 (accessed September 2007).
49. Fukuda T, Matsumoto C, Honda Y, Sugiyama N, Morishima Y, Shibano T. Antithrombotic properties of DU-176b, a novel, potent and orally active direct Factor Xa inhibitor in rat models of arterial and venous thrombosis: comparison with fondaparinux, an antithrombin dependent Factor Xa inhibitor. ASH Annual Meeting Abstracts 2004;104:1852.
50. Zafar MU, Gaztanga J, Velez M, Vorchheimer DA, Choi B, Viles-Gonzalez J, Moreno P, Fuster V, Badimon JJ. A phase-I study to assess the antithrombotic properties of DU-176b: an orally active direct Factor-Xa inhibitor. (Abstract 908-161). J Am Coll Cardiol 2006;47:288A.
51. Luettgen JM, Bozarth TA, Bozarth JM, Barbera FA, Lam PY, Quan ML, Pinto DJ, Wexler RR, Rendina AR, Knabb R. In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable Factor Xa inhibitor. (Abstract 4130). Blood 2006;108.
52. He K, He B, Grace JE, Xin B, Zhang D, Pinto DJ, Luettgen JM, Knabb RM, Lam PY, Wexler RR, Humphreys WG, Shyu W. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective Factor Xa inhibitor. (Abstract 910). Blood 2006;108.
53. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007, in press.
54. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. A phase II randomized, double-blind, eight-arm, parallel-group, dose-response study of apixaban, a new oral Factor Xa inhibitor for the prevention of deep vein thrombosis in knee replacement surgery on behalf of the apixaban investigators. (Abstract 574). Blood 2006;108.
55. Buller HR. A dose finding study of the oral direct Factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli investigators. (Abstract O-S-003). J Thromb Haemost 2007;5.
56. Abe K, Siu G, Edwards S, Lin PH, Zhu BY, Marzec U, Hanson S, Pak Y, Hollenbach S, Sinha U. Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral Factor Xa inhibitor. (Abstract 901). Blood 2006;108.
57. Turpie AG, Gent M, Bauer K, Davidson BL, Fisher WD, Huo M, Borow K. Evaluation of the Factor Xa (FXa) inhibitor, PRT054021 (PRT021), against enoxaparin in a randomized trial for the prevention of venous thromboembolic events after total knee replacement (EXPERT). (Abstract P-T-652). J Thromb Haemost 2007;5.
58. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514-521.
59. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-421.
60. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban - an oral, direct Factor Xa inhibitor. (Abstract 905). Blood 2006;108.
61. Depasse F, Busson J, Mnich J, Le Flem L, Gerotziafas GT, Samama MM. Effect of BAY 59-7939 - a novel, oral, direct Factor Xa inhibitor - on clot-bound Factor Xa activity in vitro. (Abstract P1104). J Thromb Haemost 2005;3.
62. Perzborn E, Strassburger J, Wilmen A, Lampe T, Pernerstorfer P, Pohlmann J, Roehrig S, Schlemmer K-H, Straub A. Biochemical and pharmacologic properties of BAY 59-7939, an oral, direct Factor Xa inhibitor. (Abstract PO079). Pathophysiol Haemost Thromb 2004;33(Suppl. 2).
63. Biemond BJ, Perzborn E, Friederich PW, Levi M, Buetehorn U, Buller HR. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 59-7939) - an oral, direct factor Xa inhibitor. Thromb Haemost 2007;97:471-477.
64. Perzborn E, Arndt B, Harwardt M, Lange U, Fischer E, Trabant A. Antithrombotic efficacy of BAY 59-7939 - an oral, direct Factor Xa inhibitor - compared with fondaparinux in animal arterial thrombosis and thromboembolic death models. (Abstract). Eur Heart J 2005;26(suppl.):481.
65. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-880.
66. 14C]BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rat, dog and human. (Abstract 196). Drug Metab Rev 2004;36(Suppl. 1):98.
67. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct Factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol 2006;46:981-990.
68. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin. (Abstract 11). J Clin Pharmacol 2006;46:702.
69. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:549-558.
70. Kubitza D, Mueck W, Becka M. The oral, direct Factor Xa inhibitor BAY 59-7939 does not prolong the QTc interval. (Abstract 12). J Clin Pharmacol 2006;46:703.
71. Lassen MR, Turpie AGG, Rosencher N, Borris L, Ageno W, Lieberman JR, Bandel T-J, Misselwitz F. Rivaroxaban - an oral, direct Factor Xa inhibitor - for the prevention of venous thromboembolism in total knee replacement surgery: results of the RECORD3 study. (Abstract O-S-006B). J Thromb Haemost 2007;5.
72. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kalebo P. Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007;120:653-661.
73. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005;3:2479-2486.
74. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kalebo P. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-128.
75. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kalebo P. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006;114:2374-2381.
76. Agnelli G, Gallus A, Goldhaber S, Haas S, Huisman MV, Hull R, Kakkar AK, Misselwitz F. Treatment of acute, symptomatic, proximal deep vein thrombosis with the oral, direct Factor Xa inhibitor rivaroxaban (BAY 59-7939) - the ODIXa-DVT dose-ranging study. (Abstract). Eur Heart J 2006;27(suppl.):761.
77. Buller HR. Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-finding study. (Abstract). Eur Heart J 2006;27(suppl.):761.
78. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357:1094-1104.
79. Norman P. Medicinal Chemistry - 12th RSC-SCI Symposium (Part I), Enzyme Inhibitors, Cambridge, UK. IDdb Meeting Report 2003.
80. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost; 2006;96:274-284.
81. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303.
82. Tersteegen A, Schmidt S, Burkhardt N. Rivaroxaban - an oral, direct Factor Xa inhibitor - binds rapidly to Factor Xa. (Abstract P-W-651). J Thromb Haemost 2007;5.
83. Stangier J, Rathgen K, Gansser D, Kohlbrenner V, Stassen JM. Pharmacokinetics of BIBR 953 ZW, a novel low molecular weight direct thrombin inhibitor in healthy volunteers. Thromb Haemost 2001;86:OC2347.
84. Stassen JM, Rathgen R, Zimmermann W, Wienen W, Stangier J. Pharmacodynamics of the synthetic direct thrombin inhibitor BIBR953ZW in healthy subjects. Thromb Haemost 2001;86:OC160.
85. Hauel NH, Weinen W, Nar H, Stassen JM. Effects of the direct thrombin inhibitor BIBR953ZW and its orally prodrug BIBR1048MS on experimentally-induced clot formation and template bleeding time in rats. J Med Chem 2002;9:1757-1766.
86. Wong PC, Watson CA, Crain EJ, Luettgen JM, Ogletree ML, Wexler RR, Lam PY, Pinto DJ, Knabb RM. Effects of the Factor Xa inhibitor apixaban on venous thrombosis and hemostasis in rabbits. (Abstract 917). Blood 2006;108.
87. Frost C, Nepal S, Mosqueda-Garcia R, Shenker A. Apixaban, an oral direct Factor Xa inhibitor: single-dose safety, pharmacokinetics and pharmacodynamics in healthy volunteers. J Thromb Haemost 2007;5:P-M-665.
88. Agnelli G, Haas SK, Krueger KA, Bedding AW, Brandt JT. A phase II study of the safety and efficacy of a novel oral FXa inhibitor (LY-517717) for the prevention of venous thromboembolism following TKR or THR. (Abstract 278). Blood 2005;106.
89. Weinz C, Buetehorn U, Daehler HP, Kohlsdorfer C, Pleiss U, Sandmann S, Schlemmer KH, Schwarz T, Steinke W. Pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rats and dogs. Xenobiotica 2005;35:891-910.
90. Troconiz IF, Tillmann C, Liesenfeld KH, Schafer HG, Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 2007;47:371-382.
91. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-563.
92. Stangier J, Stahle E, Rathgen K, Seitz Ch. Pharmacokinetic and pharmacodynamics of the direct thrombin inhibitor diaigatran in elderly healthy subjects. J Thromb Haemost 2005;3:P-2207.
93. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) - an oral direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007;63:469-476.
94. Wallentin LC, Ezekowitz M, Simmers TA, Pedersen KA, Stangier J, Nehmiz G, Reilly P. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation - a dose finding trial with comparison to warfarin. (Abstract P2949). Eur Heart J 2005;26(Suppl. 1):403-617.